Abstract:BackgroundBeta blockers form one of the mainstay therapies for myocardial infarction (MI). Preclinical studies have shown efficacy and safety of thyroid hormone (TH) treatment of cardiovascular disorders. Although THs interact with the sympathoadrenal system at various levels, crosstalk between TH signaling and β‐adrenergic signaling remains poorly understood. We compared pathophysiologic and TH‐adrenergic signaling changes between therapeutic doses of triiodothyronine (T3) and metoprolol (Met) in rats with MI.MethodsFemale Sprague‐Dawley rats aged 12 weeks underwent left anterior descending coronary artery ligation (MI) or sham surgeries. T3 (5 μg/kg/d) or Met (100 mg/kg/d) were given in drinking water immediately after surgery for 8 weeks. At terminal experiments, rats were subjected to morphological, functional, and molecular examination.ResultsT3 and Met significantly enhanced left ventricular (LV) fractional shortening (LVFS 21.4±2.6% and 21.1±3.7%, respectively) compared to untreated MI (17.9±1.2%) and decreased the incidence of inducible atrial tachyarrhythmia by 87.5% and 62.5% without producing untoward effects. Although both treatments showed efficacy, T3 but not Met showed statistically significant improvements compared to MI in arrhythmia duration, left atrial diameter (T3 vs MI 4.3±0.6 vs. 5.7±1.3 mm, p<0.05; Met 4.9±1.1), fibrosis (6.1±0.6%, 6.6±0.6% vs. 8.2±0.7%, T3, Met vs. MI, respectively) and aortic vasorelaxation responsiveness (pD2 6.97±0.22, 6.83±0.21 vs. 6.66±0.22, T3, Met vs MI, respectively). Quantitative PCR showed that T3 and Met attenuated expression of genes associated with inflammation and oxidative stress and restored expression of ion channels and contractile proteins compared to MI rats. Importantly, thyroid and β‐adrenergic signaling genes were favorably regulated by both treatments.ConclusionThese results support comparable efficacy of long‐term treatment with a physiological dose of T3 that is comparable to Met and suggest a potential therapeutic alternative to standard β‐blockade for patients intolerant to treatment with β‐blockers after MI.Support or Funding InformationThis work was supported by the National Heart, Lung, and Blood Institute of the NIH, Bethesda, MD, under Award Number R01HL103671 (AG). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We also acknowledged the National Natural Science Foundation of China (No. 81470485), Capital Clinical Featured Application Research Project (NO. z151100004015175) and CAMS Innovation Fund for Medical Sciences (CIFMS 2016‐I2M‐1‐009).This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Comparative Transcriptome Analysis Reveals the Potential Cardiovascular Protective Targets of the Thyroid Hormone Metabolite 3-Iodothyronamine (3-T1AM).

Thyroid Hormone Metabolite 3-Iodothyronamine (T1AM) Alleviates Hypoxia/Reoxygenation-Induced Cardiac Myocyte Apoptosis via Akt/FoxO1 Pathway

T1AM Attenuates the Hypoxia/Reoxygenation-Induced Necroptosis of H9C2 Cardiomyocytes Via RIPK1/RIPK3 Pathway

Transcriptome, Network Analysis, and Molecular Docking Approaches to Elucidate the Modes of Action of Astragaloside IV Against Myocardial Infarction with Mitochondrial Energy Metabolism Network-Targeted Regulation

High Content Screening Identifies Licoisoflavone A As a Bioactive Compound of Tongmaiyangxin Pills to Restrain Cardiomyocyte Hypertrophy Via Activating Sirt3.

Crosstalk Between Thyroid Hormone Signaling and Β‐adrenergic Signaling in Myocardial Infarction

Novel Transcriptomic Interactomes of Noncoding RNAs in the Heart under Altered Thyroid Hormonal States

Comparison of Therapeutic Triiodothyronine Versus Metoprolol in the Treatment of Myocardial Infarction in Rats

The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches

Effects of Thyroid Hormone Status on Metabolic Pathways of Arachidonic Acid in Mice and Humans: A Targeted Metabolomic Approach.

Short term triiodo-L-thyronine treatment inhibits cardiac myocyte apoptosis in border area after myocardial infarction in rats.

3-iodothyronamine inhibits apoptosis induced by myocardial ischemia reperfusion via the Akt/FoxO1 signaling pathway

Alterations of Cardiac Alpha(1)-Adrenoceptor Subtypes in Hypothyroid Rats

Abstract P247: Triiodothyronine Ameliorates Endothelial Dysfunction in Rats Following Acute Myocardial Infarction

3-Iodothyronamine reduces insulin secretion in vitro via a mitochondrial mechanism

Nanoscale organization of cardiac calcium channels is dependent on thyroid hormone status

Alterations of Α1-Adrenoceptor Subtypes in the Hearts of Thyroxine-Treated Rats

The Relationship Between Thyroid Hormone Levels and Cardiac Function in Patients with Acute Myocardial Infarction

Triiodothyronine Maintains Cardiac Transverse-Tubule Structure and Function.

Correlation of Triiodothyronine Level with In-Hospital Cardiac Function and Long-Term Prognosis in Patients with Acute Myocardial Infarction

Thyroid hormone receptors in control of heart rate